News

Lincoln Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 28 May 2026, inter alia, have recommended the final dividend of Rs 1.8 per equity Share (i.e. 18%) , subject to the approval of the shareholders.

Net profit of Lincoln Pharmaceuticals rose 0.43% to Rs 11.63 crore in the quarter ended March 2026 as against Rs 11.58 crore during the previous quarter ended March 2025. Sales rose 11.36% to Rs 187.28 crore in the quarter ended March 2026 as against Rs 168.18 crore during the previous quarter ended March 2025.For the full year,net profit rose 6.73% to Rs 87.89 crore in the year ended March 2026 as against Rs 82.35 crore during the previous year ended March 2025. Sales rose 7.67% to Rs 671.03 crore in the year ended March 2026 as against Rs 623.23 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales187.28168.18 11 671.03623.23 8 OPM %13.2715.89 -14.5616.28 - PBDT20.3919.47 5 130.12122.09 7 PBT16.7016.25 3 115.63109.19 6 NP11.6311.58 0 87.8982.35 7 Powered by Capital Market - Live News

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 May 2026.

Net profit of Lincoln Pharmaceuticals rose 37.70% to Rs 28.60 crore in the quarter ended December 2025 as against Rs 20.77 crore during the previous quarter ended December 2024. Sales rose 13.49% to Rs 166.32 crore in the quarter ended December 2025 as against Rs 146.55 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales166.32146.55 13 OPM %14.1816.14 - PBDT38.4431.91 20 PBT34.7228.68 21 NP28.6020.77 38 Powered by Capital Market - Live News

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News